Tissue Regenix Group, a regenerative medical devices group, has appointed Mike Barker as chief financial officer. He has been interim CFO since the start of 2019. A spin-out of the University of Leeds, UK, Tissue Regenix has technology to remove DNA and other cellular material from animal and human soft tissue leaving an acellular scaffold that can be used in treatments for patients. Mr Barker is a chartered accountant with experience in both AIM-listed and private businesses.
Tissue Regenix announced the appointment on 28 August 2019.
Copyright 2019 Evernow Publishing Ltd.